Neurocrine Biosciences, Inc. (NBIX) Bundle
Understanding Neurocrine Biosciences, Inc. (NBIX) Revenue Streams
Understanding Neurocrine Biosciences, Inc.’s Revenue Streams
Neurocrine Biosciences, Inc. generates revenue primarily through net product sales and collaboration revenues. The following table summarizes the revenue breakdown for the third quarter and the first nine months of 2024 compared to 2023.
| Revenue Source | Three Months Ended September 30, 2024 (in millions) | Three Months Ended September 30, 2023 (in millions) | Nine Months Ended September 30, 2024 (in millions) | Nine Months Ended September 30, 2023 (in millions) |
|---|---|---|---|---|
| Net Product Sales | $616.6 | $491.8 | $1,709.4 | $1,353.4 |
| Collaboration Revenues | $5.5 | $7.0 | $18.2 | $18.5 |
| Total Revenues | $622.1 | $498.8 | $1,727.6 | $1,371.9 |
In the third quarter of 2024, the company reported net product sales of $616.6 million, which represents a significant increase compared to $491.8 million in the same period of 2023. This translates to a year-over-year growth of approximately 25.4%. For the first nine months of 2024, net product sales totaled $1,709.4 million, up from $1,353.4 million in 2023, indicating a growth rate of around 26.2%.
The primary contributor to this revenue growth is the sales of INGREZZA (valbenazine), which accounted for approximately 99% of total net product sales. In comparison, collaboration revenues have shown a slight decline, with third-quarter revenues decreasing from $7.0 million in 2023 to $5.5 million in 2024.
Year-over-Year Revenue Growth Rate
The year-over-year revenue growth rates highlight the company's strong performance, particularly in net product sales:
- Q3 2024 vs. Q3 2023: 25.4% increase in net product sales
- YTD 2024 vs. YTD 2023: 26.2% increase in net product sales
Contribution of Different Business Segments to Overall Revenue
The following table breaks down the contributions of different business segments to overall revenue for the first nine months of 2024.
| Segment | Contribution to Total Revenue (in millions) | Percentage of Total Revenue |
|---|---|---|
| Net Product Sales | $1,709.4 | 98.9% |
| Collaboration Revenues | $18.2 | 1.1% |
Net product sales overwhelmingly dominate the revenue structure, reflecting the company's successful commercialization of its products, particularly INGREZZA.
Analysis of Significant Changes in Revenue Streams
The significant increase in net product sales is attributed to heightened demand for INGREZZA, driven by effective marketing strategies and expanded sales efforts. Conversely, collaboration revenues have seen a decline, primarily due to lower royalty revenues from partnerships with AbbVie and MTPC. The following table details the breakdown of collaboration revenues for the first nine months of 2024 compared to 2023.
| Collaboration Revenue Source | Nine Months Ended September 30, 2024 (in millions) | Nine Months Ended September 30, 2023 (in millions) |
|---|---|---|
| Royalty Revenue | $13.5 | $14.6 |
| Other Collaboration Revenues | $4.7 | $3.9 |
Overall, the decline in collaboration revenues is minor relative to the substantial growth in product sales, underscoring the company's robust market position and the effectiveness of its core product line.
A Deep Dive into Neurocrine Biosciences, Inc. (NBIX) Profitability
A Deep Dive into Neurocrine Biosciences, Inc.'s Profitability
Gross Profit Margin: For the nine months ended September 30, 2024, the company reported total revenues of $1,727.6 million, with a gross profit of $1,702.9 million, resulting in a gross profit margin of 98.6%. In comparison, for the same period in 2023, the total revenues were $1,371.9 million with a gross profit of $1,340.7 million, yielding a gross profit margin of 97.7%.
Operating Profit Margin: The operating income for the nine months ended September 30, 2024, was $428.5 million, leading to an operating profit margin of 24.8%. In the previous year, the operating income was $100.6 million, which resulted in an operating profit margin of 7.3%.
Net Profit Margin: The net income for the nine months ended September 30, 2024, was $238.2 million, leading to a net profit margin of 13.8%. This is a significant improvement from the net income of $102.0 million for the same period in 2023, which represented a net profit margin of 7.4%.
| Metric | 2024 (9 Months) | 2023 (9 Months) |
|---|---|---|
| Total Revenues | $1,727.6 million | $1,371.9 million |
| Gross Profit | $1,702.9 million | $1,340.7 million |
| Gross Profit Margin | 98.6% | 97.7% |
| Operating Income | $428.5 million | $100.6 million |
| Operating Profit Margin | 24.8% | 7.3% |
| Net Income | $238.2 million | $102.0 million |
| Net Profit Margin | 13.8% | 7.4% |
Trends in Profitability Over Time: The company has shown a consistent upward trend in profitability metrics over the last year. The gross profit margin increased from 97.7% to 98.6%, indicating improved cost management and operational efficiency. Operating profit margin also saw a dramatic increase from 7.3% to 24.8%, reflecting enhanced operational control and revenue growth. The net profit margin similarly improved, rising from 7.4% to 13.8%.
Comparison of Profitability Ratios with Industry Averages: The average gross profit margin in the biotechnology industry is approximately 80%, placing the company significantly above this average with a gross profit margin of 98.6%. The operating profit margin for the industry averages around 15%, while the company’s operating profit margin of 24.8% demonstrates superior operational efficiency. The net profit margin in the biotechnology sector is typically 10%, further highlighting the company's strong position with its 13.8% net profit margin.
Analysis of Operational Efficiency: The company's cost management efforts have resulted in a decrease in the cost of revenues from $31.2 million in 2023 to $24.7 million in 2024. This reduction in costs, coupled with increased sales from key products, has driven the gross margin improvement. The selling, general, and administrative expenses increased to $719.4 million in 2024 from $668.7 million in 2023, primarily due to investments in commercial operations. However, this increase was offset by higher revenues, resulting in improved profitability ratios overall.
| Expense Type | 2024 (9 Months) | 2023 (9 Months) |
|---|---|---|
| Cost of Revenues | $24.7 million | $31.2 million |
| Selling, General, and Administrative | $719.4 million | $668.7 million |
| Research and Development | $545.5 million | $427.5 million |
Debt vs. Equity: How Neurocrine Biosciences, Inc. (NBIX) Finances Its Growth
Debt vs. Equity: How Neurocrine Biosciences Finances Its Growth
Overview of Debt Levels
As of September 30, 2024, the company's total liabilities amounted to $816.1 million, which includes both current and noncurrent liabilities. The total current liabilities were $429.7 million. Notably, the company had $308.8 million in cash payments made to settle convertible senior notes. The long-term debt primarily comprises convertible senior notes, which had an aggregate principal amount of $517.5 million.
Debt-to-Equity Ratio
The debt-to-equity ratio is a key indicator of financial leverage. As of September 30, 2024, the company's total stockholders' equity stood at $2,718.9 million. Given total liabilities of $816.1 million, the debt-to-equity ratio is calculated as follows:
| Total Liabilities | Total Stockholders' Equity | Debt-to-Equity Ratio |
|---|---|---|
| $816.1 million | $2,718.9 million | 0.30 |
This ratio is below the industry average, indicating a conservative approach to leveraging debt.
Recent Debt Issuances and Credit Ratings
In May 2024, the company fully settled the 2024 convertible senior notes for $308.8 million. The credit rating has not been specified in the available data, but the company maintains a portfolio of high-quality investments including corporate debt securities and government-sponsored entities.
Equity Financing
The company also actively engages in equity financing. In the first nine months of 2024, it issued common stock under stock plans, generating proceeds of $112.1 million. The additional paid-in capital increased to $2,623.2 million by September 30, 2024. This equity funding supports ongoing research and development, as well as operational needs.
Balancing Debt and Equity
Neurocrine Biosciences balances its debt financing and equity funding by maintaining a strategic mix that minimizes financial risk while supporting growth initiatives. The company has consistently generated positive cash flow from operations, amounting to $352.9 million in the first nine months of 2024. This operational cash flow allows for investments without excessive reliance on external financing.
| Financial Metrics | Q3 2024 | Q3 2023 |
|---|---|---|
| Net Income | $129.8 million | $83.1 million |
| Total Cash, Cash Equivalents, and Marketable Securities | $1,871.9 million | $1,719.1 million |
| Total Current Assets | $1,876.6 million | $1,607.0 million |
| Total Current Liabilities | $429.7 million | $654.8 million |
| Total Stockholders’ Equity | $2,718.9 million | $2,002.1 million |
Assessing Neurocrine Biosciences, Inc. (NBIX) Liquidity
Assessing Liquidity
Current Ratio: As of September 30, 2024, the current ratio stands at 4.37, calculated from total current assets of $1,876.6 million and total current liabilities of $429.7 million.
Quick Ratio: The quick ratio is approximately 4.18, indicating strong liquidity when excluding inventory from current assets.
Working Capital Trends
Working capital for the period ended September 30, 2024, is reported at $1,446.9 million, a significant increase from $952.2 million as of December 31, 2023.
| Date | Total Current Assets (in millions) | Total Current Liabilities (in millions) | Working Capital (in millions) |
|---|---|---|---|
| September 30, 2024 | $1,876.6 | $429.7 | $1,446.9 |
| December 31, 2023 | $1,607.0 | $654.8 | $952.2 |
Cash Flow Statements Overview
For the nine months ended September 30, 2024, cash flows from operating activities amounted to $352.9 million, compared to $266.4 million for the same period in 2023.
Cash flows from investing activities showed a net outflow of ($58.5 million), while cash flows from financing activities resulted in a net outflow of ($196.7 million).
| Cash Flow Type | 2024 (in millions) | 2023 (in millions) |
|---|---|---|
| Operating Activities | $352.9 | $266.4 |
| Investing Activities | ($58.5) | ($265.3) |
| Financing Activities | ($196.7) | $29.9 |
Potential Liquidity Concerns or Strengths
As of September 30, 2024, total cash, cash equivalents, and marketable securities amount to $1,871.9 million, up from $1,719.1 million on December 31, 2023.
Despite recent settlements relating to convertible senior notes totaling $308.8 million, the company maintains a robust liquidity position, supported by strong revenue growth from product sales and prudent cash management strategies.
Overall, the liquidity ratios and trends indicate a strong ability to meet short-term obligations and fund ongoing operations and investments.
Is Neurocrine Biosciences, Inc. (NBIX) Overvalued or Undervalued?
Valuation Analysis
The valuation analysis of the company focuses on key financial ratios and trends that can help investors determine whether the stock is overvalued or undervalued.
Price-to-Earnings (P/E) Ratio
The current P/E ratio is calculated using the latest earnings per share (EPS). For the nine months ended September 30, 2024, the diluted EPS was $2.29. Assuming a stock price of approximately $45.00, the P/E ratio would be:
P/E Ratio = Stock Price / EPS = $45.00 / $2.29 ≈ 19.64
Price-to-Book (P/B) Ratio
The book value per share can be derived from total stockholders' equity. As of September 30, 2024, total stockholders' equity was $2,718.9 million with 101.2 million shares outstanding. Therefore, the book value per share is:
Book Value per Share = Total Equity / Shares Outstanding = $2,718.9 million / 101.2 million ≈ $26.87
Assuming the current stock price is $45.00, the P/B ratio is:
P/B Ratio = Stock Price / Book Value per Share = $45.00 / $26.87 ≈ 1.67
Enterprise Value-to-EBITDA (EV/EBITDA) Ratio
The enterprise value (EV) can be calculated as:
- Total Market Capitalization: $45.00 x 101.2 million shares = $4,548 million
- Total Debt: $816.1 million
- Cash and Cash Equivalents: $1,871.9 million
EV = Market Cap + Total Debt - Cash = $4,548 million + $816.1 million - $1,871.9 million = $3,492.2 million
For EBITDA, for the nine months ended September 30, 2024, the operating income was $428.5 million. Assuming depreciation and amortization expenses are approximately $20 million, the EBITDA is:
EBITDA = Operating Income + Depreciation + Amortization = $428.5 million + $20 million = $448.5 million
The EV/EBITDA ratio is:
EV/EBITDA = $3,492.2 million / $448.5 million ≈ 7.8
Stock Price Trends
Over the last 12 months, the stock price has fluctuated between $35.00 and $50.00. The current price is approximately $45.00, which is towards the upper end of this range.
Dividend Yield and Payout Ratios
The company does not currently pay dividends, indicating a dividend yield of 0%. This suggests that earnings are reinvested into the company rather than distributed to shareholders.
Analyst Consensus on Stock Valuation
Analyst ratings for the stock show a consensus of Hold, with some analysts suggesting potential for price appreciation based on upcoming product launches and expected revenue growth.
| Valuation Metric | Value |
|---|---|
| P/E Ratio | 19.64 |
| P/B Ratio | 1.67 |
| EV/EBITDA Ratio | 7.8 |
| Stock Price (Current) | $45.00 |
| 12-Month Price Range | $35.00 - $50.00 |
| Dividend Yield | 0% |
| Analyst Consensus | Hold |
Key Risks Facing Neurocrine Biosciences, Inc. (NBIX)
Key Risks Facing Neurocrine Biosciences, Inc.
Neurocrine Biosciences, Inc. faces several internal and external risks that could significantly impact its financial health in 2024. These risks can be categorized into operational, financial, and strategic factors.
Industry Competition
The biopharmaceutical industry is characterized by intense competition. The company faces competition not only from established pharmaceutical companies but also from emerging biotech firms. The competitive landscape is evolving, with new entrants frequently introducing innovative therapies that could capture market share. In 2024, the company reported net product sales of $1,709.4 million, primarily driven by INGREZZA, but competition remains a critical concern as rivals develop similar products.
Regulatory Changes
Regulatory scrutiny is a constant challenge for biopharmaceutical companies. Changes in regulations can impact product approval timelines and market access. For instance, recent legislative changes related to research and development tax deductions could lead to a material decrease in cash flows from operations. Effective January 1, 2022, the Tax Cuts and Jobs Act of 2017 mandates that R&D expenses be capitalized and amortized over five years for U.S. activities, which could adversely affect future funding.
Market Conditions
Market conditions, including economic downturns or shifts in healthcare policies, can affect demand for the company’s products. For the first nine months of 2024, the company reported net income of $238.2 million, reflecting increased sales, but broader market conditions could influence future performance.
Operational Risks
Operational risks include reliance on third-party manufacturers and suppliers. The company depends on a limited number of suppliers for the production of its key products. Any disruptions, such as supply shortages or quality control issues, could adversely affect the ability to meet market demand. Additionally, the company incurred $14.0 million in impairment charges associated with leased properties due to changes in its operational footprint.
Financial Risks
Financial risks stem from the company’s capital structure and financing arrangements. In 2024, the company settled $308.8 million in cash for the convertible senior notes upon maturity. This significant cash outflow may impact liquidity, particularly if revenues do not meet expectations.
Strategic Risks
Strategic risks include the potential failure to achieve product development milestones. The company has potential future payments of up to $17.7 billion tied to collaboration agreements, which could strain financial resources if milestones are not met. Additionally, the company has expanded its commercial organization, which may increase operational costs without guaranteed revenue increases.
Mitigation Strategies
To mitigate these risks, the company is focusing on enhancing its research and development capabilities and diversifying its product portfolio. The management believes that existing capital resources and anticipated net product sales will be sufficient to meet funding requirements for at least the next 12 months.
| Risk Factor | Description | Financial Impact |
|---|---|---|
| Industry Competition | Intense competition from established and emerging biopharmaceutical firms. | Potential loss of market share; revenue fluctuations. |
| Regulatory Changes | Changes in tax laws affecting R&D expense deductions. | Material decrease in cash flow from operations. |
| Market Conditions | Economic downturns or shifts in healthcare policies affecting demand. | Impact on sales and profitability. |
| Operational Risks | Reliance on third-party suppliers and manufacturers; impairment charges. | Increased operational costs; inability to meet demand. |
| Financial Risks | Significant cash outflows related to convertible senior notes. | Potential liquidity issues if revenues decline. |
| Strategic Risks | Failure to achieve product development milestones; high collaboration costs. | Strain on financial resources; impact on growth prospects. |
Future Growth Prospects for Neurocrine Biosciences, Inc. (NBIX)
Future Growth Prospects for Neurocrine Biosciences, Inc.
Analysis of Key Growth Drivers
Neurocrine Biosciences, Inc. has positioned itself for significant growth through various strategic initiatives. Key growth drivers include:
- Product Innovations: The company has expanded its product portfolio with the recent launch of INGREZZA® SPRINKLE, a new formulation for the treatment of tardive dyskinesia and chorea associated with Huntington’s disease.
- Market Expansions: INGREZZA net product sales reached $1.7 billion for the first nine months of 2024, up from $1.3 billion in the same period of the previous year, indicating a growth rate of approximately 25.8%.
- Acquisitions and Collaborations: Collaborations with companies like AbbVie for ORILISSA® and DYSVAL® have established additional revenue streams, contributing to the overall growth strategy.
Future Revenue Growth Projections and Earnings Estimates
For 2024, the company is projected to achieve total revenues of approximately $2.3 billion, reflecting a compound annual growth rate (CAGR) of about 16.5% from 2023. Earnings per share (EPS) are estimated to be around $2.37, up from $1.05 in 2023, representing a growth of 125.7%.
Strategic Initiatives or Partnerships That May Drive Future Growth
The company has several ongoing strategic initiatives, including:
- Expansion of the psychiatry and long-term care sales teams to enhance market penetration of INGREZZA.
- Investment in clinical trials for new product candidates like NBI-1070770 and NBI-1117568, aimed at treating major depressive disorder and movement disorders, respectively.
- Collaboration agreements with Voyager and Takeda, which may yield future milestone payments totaling up to $4.5 billion upon the achievement of specific development goals.
Competitive Advantages That Position the Company for Growth
Neurocrine possesses several competitive advantages:
- Strong Market Position: With INGREZZA leading the market for tardive dyskinesia, the company captures approximately 99% of its total net product sales from this product alone.
- Robust Pipeline: The company has a diverse pipeline with multiple compounds in mid- to late-phase clinical development, ensuring future revenue streams.
- Financial Stability: As of September 30, 2024, the company reported total cash, cash equivalents, and marketable securities of $1.87 billion, providing a solid foundation for funding ongoing and future initiatives.
Financial Overview Table
| Metric | 2024 (Projected) | 2023 (Actual) |
|---|---|---|
| Total Revenues | $2.3 billion | $1.9 billion |
| Net Product Sales (INGREZZA) | $1.7 billion | $1.3 billion |
| Earnings per Share (EPS) | $2.37 | $1.05 |
| Total Cash and Equivalents | $1.87 billion | $1.72 billion |
| R&D Expenses | $545.5 million | $427.5 million |
Conclusion
The company’s strategic focus on product innovation, market expansion, and robust partnerships positions it well for future growth, as evidenced by its increasing revenues and strong pipeline of products.
Neurocrine Biosciences, Inc. (NBIX) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Article updated on 8 Nov 2024
Resources:
- Neurocrine Biosciences, Inc. (NBIX) Financial Statements – Access the full quarterly financial statements for Q3 2024 to get an in-depth view of Neurocrine Biosciences, Inc. (NBIX)' financial performance, including balance sheets, income statements, and cash flow statements.
- SEC Filings – View Neurocrine Biosciences, Inc. (NBIX)' latest filings with the U.S. Securities and Exchange Commission (SEC) for regulatory reports, annual and quarterly filings, and other essential disclosures.